Autopsy report · NCT01086982
Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®
Cause of deathNo reason given
Life of this trial
- Suspended: paused, and may or may not restart.
- 16 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 1
- Sponsor
- Azidus Brasil
- Sponsor type
- Industry
- Conditions
- Acromegaly
- Interventions
- Octreotide acetate LAR; Sandostatin LAR ® (octreotide acetate LAR) 30 MG
- Participants
- 16 (planned, not actual)
- Sites
- 1
- Countries
- Brazil
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.